Literature DB >> 4212341

Sodium cromoglycate (cromolyn sodium): a review of its mode of action, pharmacology, therapeutic efficacy and use.

R N Brogden, T M Speight, G S Avery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4212341     DOI： 10.2165/00003495-197407030-00002

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  217 in total

Review 1.  Immunopathology of allergic lung disease.

Authors:  J Pepys
Journal:  Clin Allergy       Date:  1973-03

2.  Allergic reactions of the lungs to enzymes of Bacillus subtilis.

Authors:  J Pepys; J L Longbottom; F E Hargreave; J Faux
Journal:  Lancet       Date:  1969-06-14       Impact factor: 79.321

3.  Effect of disodium cromoglycate on asthmatic reactions to alcoholic beverages.

Authors:  A B Breslin; D J Hendrick; J Pepys
Journal:  Clin Allergy       Date:  1973-03

4.  Increased dosage of disodium cromoglycate.

Authors:  J M Smith
Journal:  Br Med J       Date:  1973-05-05

5.  A double-blind trial of disodium cromoglycate in bronchial asthma wh assessment by four observers.

Authors:  I Weinbren; J Bound; L Capper
Journal:  Br J Dis Chest       Date:  1969-07

6.  Effect of disodium cromoglycate on exercise-induced asthma.

Authors:  S E Davies
Journal:  Br Med J       Date:  1968-09-07

7.  Treatment of asthmatic children for six months with disodium cromoglycate: progress report from a long-term study.

Authors:  S Bedford; J A Kuzemko
Journal:  Clin Pediatr (Phila)       Date:  1970-12       Impact factor: 1.168

8.  Disodium cromoglycate (FPL 670) ('Intal'): a specific inhibitor of reaginic antibody-antigen mechanisms.

Authors:  J S Cox
Journal:  Nature       Date:  1967-12-30       Impact factor: 49.962

9.  Plasma levels and urinary excretion of disodium cromoglycate afer inhalation by human volunteers.

Authors:  G F Moss; K M Jones; J T Ritchie; J S Cox
Journal:  Toxicol Appl Pharmacol       Date:  1971-10       Impact factor: 4.219

10.  [Results with DSCG (Lomudal) in the treatment of bronchial asthma, especially of pollen asthma].

Authors:  B Wüthrich
Journal:  Respiration       Date:  1970       Impact factor: 3.580
View more
  21 in total

1.  The orally administered anti-allergic agent, sodium nivimedone (BRL 10833); efficacy in bronchial asthma and effects on IgE, complement and eosinophils.

Authors:  E M Lumb; G J McHardy; A B Kay
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

Review 2.  Lung inflammation, its significance for asthma therapy.

Authors:  J Morley; D Smith
Journal:  Agents Actions       Date:  1989-01

Review 3.  The role of allergy in sinus disease. Children and adults.

Authors:  Z Pelikan
Journal:  Clin Rev Allergy Immunol       Date:  1998 Spring-Summer       Impact factor: 8.667

Review 4.  Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease.

Authors:  E M Sorkin; A Ward
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

Review 5.  Antiasthmatic drugs. II. Therapeutic aspects.

Authors:  A S Rebuck
Journal:  Drugs       Date:  1974       Impact factor: 9.546

6.  Newer non-sedating antihistamines. Will they replace older agents?

Authors:  M L Brandon
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

7.  Dosage adjustment in renal insufficiency.

Authors:  G E Mawer
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

8.  New perspectives in allergic asthma.

Authors:  S O Freedman
Journal:  Can Med Assoc J       Date:  1976-02-21       Impact factor: 8.262

9.  Determination of the antiulcer properties of sodium cromoglycate in pylorus-ligated albino rats.

Authors:  Vivek Srivastava; A H M Viswanathaswamy; Govind Mohan
Journal:  Indian J Pharmacol       Date:  2010-06       Impact factor: 1.200

10.  Treatment of atopic eczema in children: clinical trial of 10% sodium cromoglycate ointment.

Authors:  S A Haider
Journal:  Br Med J       Date:  1977-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.